These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20412322)

  • 1. BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study.
    Windyga J; Rusen L; Gruppo R; O'Brien AC; Kelly P; Roth DA; Arkin S
    Haemophilia; 2010 Sep; 16(5):731-9. PubMed ID: 20412322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.
    Recht M; Nemes L; Matysiak M; Manco-Johnson M; Lusher J; Smith M; Mannucci P; Hay C; Abshire T; O'Brien A; Hayward B; Udata C; Roth DA; Arkin S
    Haemophilia; 2009 Jul; 15(4):869-80. PubMed ID: 19473411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience.
    Stieltjes N; Altisent C; Auerswald G; Négrier C; Pouzol P; Reynaud J; Roussel-Robert V; Savidge GF; Villar A; Schulman S
    Haemophilia; 2004 Sep; 10(5):452-8. PubMed ID: 15357770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
    Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
    Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Ghandehari H; Chapman M; Fritsch S; Wong WY; Pavlova BG; Abbuehl BE
    Haemophilia; 2014 Sep; 20(5):651-8. PubMed ID: 24697870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
    Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
    Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
    Boadas A; Fernández-Palazzi F; De Bosch NB; Cedeño M; Ruiz-Sáez A
    Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Major orthopaedic surgeries for haemophilia with inhibitors using rFVIIa.
    Takedani H; Kawahara H; Kajiwara M
    Haemophilia; 2010 Mar; 16(2):290-5. PubMed ID: 19925628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.
    Lusher JM; Lee CA; Kessler CM; Bedrosian CL;
    Haemophilia; 2003 Jan; 9(1):38-49. PubMed ID: 12558777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
    Brand B; Gruppo R; Wynn TT; Griskevicius L; Lopez Fernandez MF; Chapman M; Dvorak T; Pavlova BG; Abbuehl BE
    Haemophilia; 2016 Jul; 22(4):e251-8. PubMed ID: 27328112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
    Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
    Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
    Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C
    Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies.
    Négrier C; Lienhart A; Numerof R; Stephens D; Wong WY; Baghaei F; Yee TT
    Haemophilia; 2013 May; 19(3):e143-50. PubMed ID: 23282031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies.
    Rusen L; Kavakli K; Korth-Bradley J; Huard F; Rendo P; Fuiman J; Baumann JA; Smith L; Alvey C; Rupon J
    Haemophilia; 2018 Jul; 24(4):604-610. PubMed ID: 29582525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A.
    Mahlangu JN; Ragni M; Gupta N; Rangarajan S; Klamroth R; Oldenburg J; Nogami K; Young G; Cristiano LM; Dong Y; Allen G; Pierce GF; Robinson B
    Thromb Haemost; 2016 Jul; 116(1):1-8. PubMed ID: 26962852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.
    Hyun SY; Park SY; Lee SY; Kook H; Paik SH; Jang IJ; Lee KS
    Yonsei Med J; 2015 Jul; 56(4):935-43. PubMed ID: 26069114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
    Négrier C; Shapiro A; Berntorp E; Pabinger I; Tarantino M; Retzios A; Schroth P; Ewenstein B
    Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A.
    Xue F; Zhao X; Sun J; Zeng X; Yang F; Xu M; Yu Z; Gu W; Feng Y; Li W; Zheng C; Bi H; Xie L; Gai W; Yang R
    Haemophilia; 2021 Sep; 27(5):814-822. PubMed ID: 34089210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.